N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

399

Participants

Timeline

Start Date

October 16, 2007

Primary Completion Date

August 9, 2010

Study Completion Date

August 9, 2010

Conditions
Radiocontrast Nephropathy
Interventions
DRUG

N-Acetylcysteine (NAC)

"Experimental:~* Before CT: 3 g NAC IV in 500 cc of 0.9% Sodium-chloride~* After CT: 200 mg NAC/hour in 0.9% Sodium-chloride at 67 cc/hour for up to 24 hours."

DRUG

0.9% Sodium-chloride

"Placebo:~* Before CT: 500 cc 0.9% Sodium-chloride~* After CT: NS at 67 cc/hour for up to 24 hours."

Trial Locations (1)

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors
All Listed Sponsors
collaborator

Cumberland Pharmaceuticals

INDUSTRY

lead

Beth Israel Deaconess Medical Center

OTHER